Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population
Federica Lo Prinzi(Campus Bio Medico University Hospital), Monica Niger(Fondazione IRCCS Istituto Nazionale dei Tumori), Stefano Tamberi(Azienda Unità Sanitaria Locale Della Romagna), Tiziana Pressiani(IRCCS Humanitas Research Hospital), Guido Giordano(University of Foggia), Monica Verrico(Policlinico Umberto I), Oluseyi Abidoye(Mayo Clinic), Francesca Salani(Scuola Superiore Sant'Anna), Emiliano Tamburini(Ospedale Infermi di Rimini), Margherita Rimini(Vita-Salute San Raffaele University), Masafumi Ikeda(National Cancer Center Hospital East), Alessandro Pastorino(Ospedale Policlinico San Martino), Fabian Finkelmeier(Goethe University Frankfurt), Il Hwan Kim(Louisiana State University), Alessandro Parisi(Marche Polytechnic University), Mario Scartozzi(University of Cagliari), Gerald W. Prager(Comprehensive Cancer Center Vienna), Lukas Perkhofer(University Hospital Ulm), Ricardo Roque, Lorenzo Fornaro(Azienda Ospedaliera Universitaria Pisana), Caterina Vivaldi(Scuola Superiore Sant'Anna), Florian Castet(Institut d'Investigació Biomédica de Bellvitge), Gian Paolo Spinelli(Sapienza University of Rome), Ilario Giovanni Rapposelli(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Stephen L. Chan(Chinese University of Hong Kong), Chiara Braconi(Beatson West of Scotland Cancer Centre), Marta Schirripa(Azienda Sanitaria Locale Viterbo), Anna Diana(University of Campania "Luigi Vanvitelli"), Jessica Lucchetti(Campus Bio Medico University Hospital), Jorge Adeva(Hospital Universitario 12 De Octubre), Mario Domenico Rizzato(University of Padua), Hanne Vandeputte(KU Leuven), Nicola Personeni(IRCCS Humanitas Research Hospital), Maria Grazia Rodriquenz(Casa Sollievo della Sofferenza), Ester Oneda(Fondazione Poliambulanza Istituto Ospedaliero), Federico Rossari(Vita-Salute San Raffaele University), Hong Jae Chon(CHA University Bundang Medical Center), Ingrid Garajová(University of Parma), Daniele Lavacchi(University of Florence), Jeroen Dekervel(Universitair Ziekenhuis Leuven), Chiara Pircher(Fondazione IRCCS Istituto Nazionale dei Tumori), Cecilia Melo Alvim(Hospital de Santa Maria), Tomoyuki Satake(National Cancer Center Hospital East), Antonio Avallone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Changhoon Yoo(Ulsan College), Jin Won Kim(Seoul National University Bundang Hospital), Antonio De Rosa(Istituto Oncologico Veneto), Lorenzo Antonuzzo(Azienda Ospedaliero-Universitaria Careggi), Silvana Leo(Ospedale Vito Fazzi), Silvia Camera(Vita-Salute San Raffaele University)
Cited by 10
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k